RZRan Zhao

Ran Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ran Zhao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Yingwei Chen

    Shanghai Center for Clinical Laboratory Shanghai China

    2 shared publications
  • Chaoran Xia

    Zhejiang Shaoxing Topgen Biomedical Technology CO., LTD. Shanghai China

    1 shared publication
  • Chengxiang Chu

    Shanghai Center for Clinical Laboratory Shanghai China

    1 shared publication
  • Chunli Shi

    Shanghai Center for Clinical Laboratory Shanghai China

    1 shared publication
  • Dongge Xia

    Department of Clinical Laboratory Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

    1 shared publication
  • Fangying Ruan

    Zhejiang Shaoxing Topgen Biomedical Technology CO., LTD. Shanghai China

    1 shared publication

Latest Publications

  • Performance of Two Molecular Point‐of‐Care Influenza A/B Tests Compared to the Cepheid Xpert Xpress Flu/RSV Assay

    by Ran Zhao, Xue Cai, Yingwei Chen, Zhongqiang Huang, Chengxiang Chu, Chunli Shi, Weijie Ding, Xiaobo Hu, Xueliang Wang

    Molecular point‐of‐care testing (POCT) platforms have demonstrated considerable utility in rapid and accurate influenza diagnostics. Among them, the Cepheid Xpert is widely used in clinical practice, while Coyote Flash10 and Genewise NAT‐3000 were recently approved, with few performance data available. Performances of Flash10 and NAT‐3000 were evaluated in parallel with the Xpert assay. The limits of detection (LoDs) were determined using serially diluted standard reference materials of inactivated influenza virus A and B (FluA/B). Clinical performance was assessed using 200 remnant nasopharyngeal swab specimens. Other assay features were also compared. All three platforms featured comparable hands‐on procedures and turnaround times ranging from 26 to 33 min. The Xpert assay was more sensitive than the other two, with the lowest LoDs at 72.6, 49.3, 213.2, and 66.8 copies/mL for FluA H1N1, FluA H3N2, FluB Victoria, and FluB Yamagata, respectively. The Flash10 and NAT‐3000 assays showed similar LoDs for FluA, ranging from 483.4 to 576.8 copies/mL; for Victoria and Yamagata, their LoDs were 296.4 and 92.7 copies/mL for Flash10 and 1419.1 and 591.0 copies/mL for NAT‐3000. Clinical performance revealed high concordance across assays. Positive and negative percentage agreements ranged from 93.33% to 100.00%, along with high Kappa values ranging from 0.94 to 0.95. Linear regression analysis showed moderate to strong associations between the cycle threshold values of positive specimens. The two new molecular POCT platforms were similarly user‐friendly and showed comparable performance to the Xpert platform for FluA/B detection, despite their higher LoDs, indicating they are potential alternatives for rapid respiratory virus detection.

  • Open Access

    Improved diagnosis of colorectal cancer using combined biomarkers including Fusobacterium nucleatum, fecal occult blood, transferrin, CEA, CA19‐9, gender, and age

    by Ran Zhao, Dongge Xia, Yingwei Chen, Zhentian Kai, Fangying Ruan, Chaoran Xia, Jingkai Gong, Jun Wu, Xueliang Wang

    Background: Conventional blood and stool tests are normally used for early screening of colorectal cancer (CRC) but the accuracy and efficiency remain to be improved. Recent findings suggest Fusobacterium nucleatum to be a biomarker for CRC. This study evaluated the role of F. nucleatum and developed CRC diagnostic models by combining F. nucleatum with fecal occult blood (FOB), transferrin (TRF), carcinoembryonic antigen (CEA), carbohydrate antigen 19‐9 (CA19‐9), gender, and age.Materials and Methods: Candidates including 71 healthy individuals and 59 CRC patients were recruited. Abundance of F. nucleatum in stool or tissue samples was measured by quantitative real‐time PCR. CEA, CA19‐9, TRF, and FOB were measured in parallel. These biomarkers together with genders and ages were the seven parameters used to develop CRC diagnostic models. Ten different machine learning algorithms were tested to achieve the best performance.Results: Fecal F. nucleatum abundance was found significantly higher in CRC group compared to healthy group (p = 0.0005). Among the CRC patients, F. nucleatum abundance in tumor tissue was significantly higher than that in paracancerous tissue (p = 0.0087). CRC diagnostic models using different parameters were generated based on Logistic Regression algorithm, which showed good performance. The area under the curve (AUC) score of fecal F. nucleatum as the single diagnostic biomarker was 0.68 while the accuracy was 0.56. The diagnostic performance was obviously improved with the highest AUC (0.93) and accuracy (0.87) achieved when using all the 7 clinical parameters. The combination F. nucleatum + FOB + gender + age had the second highest AUC (0.92) and accuracy (0.85). A more utilitarian model using F. nucleatum + FOB showed relatively high AUC at 0.86 and accuracy at 0.81.Conclusions: F. nucleatum is valuable for CRC diagnosis. Combination of different clinical parameters could significantly improve CRC diagnostic performance. The combination F. nucleatum + FOB + gender + age may be an effective and noninvasive method for clinical application.